Rocky Mountain Cancer Centers (Midtown)

Sorting 3 by

Accepting patients

DRAMMATIC

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)
Learn more
  • Monoclonal Antibody
  • CD38
  • Maintenance
  • Phase 3

Accepting patients

Teclistamab

A Study of Outpatient Administration of Teclistamab, a BCMA-targeting Bispecific Antibody, in Multiple Myeloma Patients
Learn more
  • Bispecific Antibody
  • BCMA
  • Phase 2

Accepting patients

Selinexor

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
Learn more
  • SINE
  • Phase 2
2 hidden based on your filters. Show All